A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis

Chunlei Zhang,Kexiang Yan,Qingchun Diao,Qing Guo,Hongzhong Jin,Sen Yang,Xiang Chen,Tiechi Lei,Jianhua Wu,Hong Yu,Min Zheng,Xinghua Gao,Rodney Sinclair,Yi Zhu,Qian Xu,Jinhua Xu

Journal of the American Academy of Dermatology（2022）

引用 8|浏览8

暂无评分

摘要

Vunakizumab showed promising efficacy for moderate-to-severe plaque psoriasis, with good tolerability, warranting further investigation in larger and longer-term studies.

查看译文

关键词

anti–IL-17A,biologics,clinical trial,plaque psoriasis,psoriasis area and severity index,quality of life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要